Brief: Selectimmune: Positive Study Results
15/04/2020 10:19
April 15 (Reuters) - Selectimmune Pharma AB SELECTb.TE :
* NEW RESULTS IN ANIMAL STUDIES SHOW THAT SELECTIMMUNE'S
IMMUNE
THERAPY NOT ONLY REDUCE HARMFUL INFLAMMATION BUT ALSO INCREASES
KILLING OF BACTERIAS IN INFECTED TISSUE
Source text for Eikon: ID:nWkr34hQt8
Further company coverage: SELECTb.TE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Selectimmune Pharma AB
See all newsBrief: Selectimmune Pharma Says Co's CEO Ann Gidner Will Leave Selectimmune Pharma
Brief: Lonza Collaborates With Selectimmune Collaborates To Develop Immunotherapeutic Drug Candidate
Brief: Selectimmune Pharma Q2 Pretax Loss Widens To SEK 3.1 Mln
Brief: Selectimmune Pharma Q1 Pretax Loss Narrows To SEK 2.2 Million
Brief: Selectimmune Pharma Signs Deal On Phase II Study For Infection Treatment